In 2019, ten-year-old Tilda died unexpectedly in her home, leaving her family and the Swedish medical community with few answers. For years, the circumstances surrounding her sudden passing remained largely unexamined by the institutions responsible for her care. However, a recent investigation has brought new scrutiny to the months leading up to her death, specifically the aggressive pharmacological intervention overseen by her pediatric cardiologist.
Evidence surfaced that the physician—already a figure of some controversy within the field—had quadrupled Tilda’s dosage of heart medication in the months before she died. The scale of the increase has raised profound questions about clinical judgment and the protocols governing high-risk pediatric treatments. While medical adjustments are common in complex cases, the magnitude of this specific change has now become the focal point of a formal inquiry.
The shift toward accountability began last autumn when Tilda’s parents demanded a comprehensive review of her treatment. Following a detailed investigation by the Swedish newspaper *Dagens Nyheter*, the hospital has officially reported the doctor’s handling of the case to regulatory authorities. The move marks a significant admission of potential failure in a system that often struggles to address clinical errors years after the fact.
With reporting from *Dagens Nyheter*.
Source · Dagens Nyheter
